Publications

Title

Author

Year

Activin A levels are raised during human tuberculosis and blockade of the activin signaling axis influences murine responses to <i>M. tuberculosis</i> infection.

Nieuwenhuizen, NE; Nouailles, G; SUTHERLAND, JS; Zyla, J; Pasternack, AH; Heyckendorf, J; Frye, BC; Höhne, K; Zedler, U; Bandermann, S; Abu Abed, U; Brinkmann, V; Gutbier, B; Witzenrath, M; Suttorp, N; Zissel, G; Lange, C; Ritvos, O; Kaufmann, SH E; CAPNETZ Study group,; DZIF TB study group,;

2024

mBio, (2024).15 3 10.1128/mbio.03408-23.

Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis.

Nimmo, C; Ortiz, AT; Tan, CC S; Pang, J; Acman, M; Millard, J; Padayatchi, N; GRANT, AD; O'Donnell, M; Pym, A; Brynildsrud, OB; Eldholm, V; Grandjean, L; Didelot, X; Balloux, F; Van Dorp, L;

2024

Genome medicine, (2024).16 1 10.1186/s13073-024-01289-5.

Author Correction: Community-based active-case finding for tuberculosis: navigating a complex minefield.

MacPherson, P; Shanaube, K; Phiri, MD; RICKMAN, HM; HORTON, KC; Feasey, HR A; CORBETT, EL; BURKE, RM; Rangaka, MX;

2024

BMC global and public health, (2024).2 1 10.1186/s44263-024-00048-3.

Quantifying non-adherence to anti-tuberculosis treatment due to early discontinuation: a systematic literature review of timings to loss to follow-up.

Walker, EF; Flook, M; Rodger, AJ; FIELDING, KL; STAGG, HR;

2024

BMJ Open Respiratory Research, (2024).11 1 10.1136/bmjresp-2023-001894.

Demonstrating the utility of the ex vivo murine mycobacterial growth inhibition assay (MGIA) for high-throughput screening of tuberculosis vaccine candidates against multiple Mycobacterium tuberculosis complex strains.

PAINTER, H; WILLCOCKS, S; Zelmer, A; Reljic, R; Tanner, R; Fletcher, H;

2024

Tuberculosis (Edinburgh, Scotland), (2024).146, 10.1016/j.tube.2024.102494.

Tracking Cryptococcal Meningitis to Monitor HIV Program Success During the Treat All Era: An Analysis of National Data in Botswana.

MILBURN, J; Ntwayagae, O; Suresh, R; Ngoni, K; Northcott, C; Penney, J; Kinsella, M; Mechie, I; Ensor, S; Thamae, G; Leeme, T; LAWRENCE, DS; Chebani, T; GRINT, D; Tenforde, MW; Avalos, A; Ramaabya, D; Ogando, J; Mokomane, M; Mine, M; JARVIS, JN;

2024

Clinical infectious diseases, (2024).79 2 10.1093/cid/ciae066.

Community-based active-case finding for tuberculosis: navigating a complex minefield.

MacPherson, P; Shanaube, K; Phiri, MD; RICKMAN, HM; HORTON, KC; Feasey, HR A; CORBETT, EL; BURKE, RM; Rangaka, MX;

2024

BMC global and public health, (2024).2 1 10.1186/s44263-024-00042-9.

Modelling the health and economic impacts ofM72/AS01E vaccination and BCG-revaccination: Estimates for South Africa.

SUMNER, T; CLARK, RA; Mukandavire, C; Portnoy, A; Weerasuriya, CK; Bakker, R; Scarponi, D; Hatherill, M; Menzies, NA; WHITE, RG;

2024

Vaccine, (2024).42 6 10.1016/j.vaccine.2024.01.072.

Molecular determinants of multidrug-resistant tuberculosis in Sierra Leone.

Blankson, HN A; Kamara, RF; Barilar, I; Andres, S; Conteh, OS; Dallenga, T; Foray, L; Maurer, F; KRANZER, K; Utpatel, C; Niemann, S;